Interleukin 17 treatments for psoriasis efficacy and safety study

[Fred]

This study evaluated the efficacy and safety of Interleukin 17 treatments for psoriasis. *Cosentyx and Taltz are Interleukin 17 treatments.

Quote:

---

Background:
The interleukin-17 (IL-17) cytokine pathway plays a key role in the development of psoriasis. Antibodies targeting IL-17 or blocking its receptor may be a new therapeutic approach for psoriasis. To assist treatment selection in daily practice, it is essential to understand the benefit and risk profile of IL-17 antagonists.

Objective:
We performed a meta-analysis to evaluate the efficacy and safety of IL-17 antagonists in patients with psoriasis.

Methods:
We searched a number of databases for relevant randomized controlled trials (RCTs) published before May 2016. The following outcomes were evaluated: Psoriasis Area and Severity Index (PASI) 75, 90, 100 response, Investigator's Global Assessment (IGA) score of 0 or 1 response, adverse events (AEs) and withdrawals. The meta-analysis was performed using Review Manager 5.2 software.

Results:
Nine RCTs with 5951 patients were included. IL-17 antagonists achieved higher PASI 75, 90, 100 response rates and Dermatology Life Quality Index 0 or 1 response rates than placebo and a lower incidence of discontinuations due to lack of efficacy. In the safety analysis, no significant differences were found between the IL-17 antagonists and placebo in the proportion of patients with serious AEs, cardiovascular disease and discontinuations due to AEs. However, IL-17 antagonists were associated with a higher proportion of patients with any AEs and infections than placebo.

Conclusion:
IL-17 antagonists were effective, with an acceptable safety profile, for patients with plaque psoriasis. Vigilance because of the potential for infection will be necessary for IL-17 antagonists.

Source: onlinelibrary.wiley.com

Conflicts of interest: The authors declare that they have no competing interests.

Funding sources: The authors received no payment in preparation of this manuscript.

Dan Wu and Si-Yuan Hou contributed equally to the work.

Cosentyx (secukinumab)

Taltz (ixekizumab)

[Caroline]

By the way from the DMF-gang...

It really seems that IL-17 is an important one !! And not only in Cosentyx or Taltz

Quote:

---

The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis.
Author information: Tahvili S1, Zandieh B2, Amirghofran Z1,3.

Abstract
BACKGROUND:
Fumaric acid esters such as dimethyl fumarate (DMF) have proven to be effective in the treatment of psoriasis.
OBJECTIVES:
In view of the role of Th17 in the pathogenesis of psoriasis, the present study was conducted to investigate the effects of DMF on Th1, Th2, and Th17 responses in patients.
METHODS:
Peripheral blood mononuclear cells (PBMCs) were isolated from psoriasis patients and healthy individuals and were cultured in the presence or absence of phytohemagglutinin and DMF. The cell supernatants were removed to measure cytokine secretion, and the lymphocytes were used for real-time polymerase chain reaction to establish gene expression.
RESULTS:
An increase in gene expression of interferon-γ (IFN-γ), as a marker for Th1 activity, and interleukin-17 (IL-17), granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-22 representing the Th17 subset in the PBMCs of patients in comparison with those of control subjects was observed. Culture of PBMCs from psoriasis patients and controls in the presence of DMF decreased IFN-γ and increased IL-4 gene expression in both groups. Treatment with DMF could significantly decrease IL-17, GM-CSF, and IL-22 mRNA levels in the PBMCs of patients. Decreased release of IFN-γ and GM-CSF cytokine secretion after DMF treatment was also observed in PBMC cultures of patients and controls.
CONCLUSIONS:
These data show the effectiveness of DMF in modulating Th17 cells in addition to Th1/Th2 cells and reflect one of the underlying mechanisms of action of DMF in psoriasis. These findings may also support the possible benefits of using fumarate in the treatment of other autoimmune diseases in the pathogeneses of which Th1 and Th17 cells play major roles.

Source: pub med
© 2015 The International Society of Dermatology.
Int J Dermatol. 2015 Jul;54(7):e254-60. doi: 10.1111/ijd.12834.